# Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer

> **NCT03829930** · PHASE1 · TERMINATED · sponsor: **George Washington University** · enrollment: 6 (actual)

## Conditions studied

- Prostate Adenocarcinoma

## Interventions

- **DRUG:** Entinostat
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT03829930
- **Lead sponsor:** George Washington University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-01
- **Primary completion:** 2020-09-01
- **Final completion:** 2020-09-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Sponsor discontinued the drug
- **Last updated:** 2021-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829930, "Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03829930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*